|
December 14, 2005 Categories: For professionals Posted by admin
This next-generation drug-eluting stent will use the popular Driver™ bare metal cobalt alloy stent platform and the drug Zotarolimus (ABT-578), along with the proprietary, biocompatible drug delivery polymer developed by Medtronic. Prof. Ian Meredith, Monash Medical Centre, is the principal investigator of the Medtronic RESOLUTE clinical study evaluating the new stent. This first-in-man study will enroll up to 100 patients at 12 clinical sites in Australia and New Zealand.
Full news
|
|
